"Factor IX" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).
| Descriptor ID |
D005164
|
| MeSH Number(s) |
D08.622.355 D12.776.124.125.375 D23.119.375
|
| Concept/Terms |
Factor IX- Factor IX
- Factor Nine
- Autoprothrombin II
- Christmas Factor
- Factor IX Fraction
- Plasma Thromboplastin Component
- Blood Coagulation Factor IX
- Factor IX Complex
- Factor 9
- Coagulation Factor IX
- Factor IX, Coagulation
|
Below are MeSH descriptors whose meaning is more general than "Factor IX".
Below are MeSH descriptors whose meaning is more specific than "Factor IX".
This graph shows the total number of publications written about "Factor IX" by people in this website by year, and whether "Factor IX" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor IX" by people in Profiles.
-
Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding. Transfus Med Rev. 2021 10; 35(4):96-103.
-
Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci U S A. 2010 Apr 13; 107(15):7101-6.
-
Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience. Haemophilia. 2008 Mar; 14(2):260-70.
-
Circulating human factor IX produced in keratin-promoter transgenic mice: a feasibility study for gene therapy of haemophilia B. Hum Mol Genet. 1995 Jun; 4(6):993-9.